Market Cap 1.27B
Revenue (ttm) 348.97M
Net Income (ttm) 5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1.68%
Debt to Equity Ratio -7.13
Volume 5,048,100
Avg Vol 5,420,226
Day's Range N/A - N/A
Shares Out 308.95M
Stochastic %K 91%
Beta 1.12
Analysts Strong Sell
Price Target $7.97

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology
Sector: Healthcare
Phone: 818 661 5000
Address:
1 Casper Street, Danbury, United States
amsteliam
amsteliam Aug. 9 at 11:25 PM
$MNKD This could go more quickly than I anticipated. Funny to say after 12 years.
0 · Reply
BenYiju
BenYiju Aug. 9 at 10:37 PM
$MNKD Mikey fired up the ATM again?!? 🤬
0 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 8:39 PM
0 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 7:57 PM
$MNKD this is a response to. How is 20 cartridges of Afrezza a day on the lungs?
0 · Reply
SS115
SS115 Aug. 9 at 7:44 PM
$MNKD Anyone know what the latest increase of 2.1 million OS count stems from? It went to 319.4 million after the initial shares from the private placement funding agreement were added but now it’s at 321.5 million. Was it from the private placement warrants being exercised, awarded shares to executives, or something else?
2 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 7:27 PM
$MNKD these two reported in the last 12 hours
1 · Reply
grampslol
grampslol Aug. 9 at 7:00 PM
$MNKD and yet pennyland it is and shall be
1 · Reply
clan
clan Aug. 9 at 6:46 PM
$MNKD The first $200,000,000 of PROFIT that Mannkind makes from its scPharma division ... will be tax-free! 🤑 @DRFSR So they got that goin' for it, which is nice. 💲 $SCPH 👍 $SPY 💲
0 · Reply
grampslol
grampslol Aug. 9 at 4:36 PM
1 · Reply
clan
clan Aug. 9 at 4:33 PM
$MNKD Afrezza, INHALABLE mealtime insulin for diabetics, is now FDA approved for kids. It's also Scott Malkinson-approved. 🚫💉 For the good of all Mannkind. 👍 $LLY 😁 $NVO 👍 $SPY 🫵
0 · Reply
Latest News on MNKD
MannKind price target lowered to $13 from $14 at Wells Fargo

2026-08-06T10:15:53.000Z - 3 days ago

MannKind price target lowered to $13 from $14 at Wells Fargo


MannKind reports Q2 EPS (6c), consensus 2c

2026-08-05T20:37:06.000Z - 4 days ago

MannKind reports Q2 EPS (6c), consensus 2c


MannKind Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

MannKind Earnings Call Transcript: Q2 2026


MannKind Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

MannKind Earnings release: Q2 2026


MannKind Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

MannKind Quarterly report: Q2 2026


MannKind Slides: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 days ago

MannKind Slides: Q2 2026


MannKind price target raised to $14 from $11 at Wells Fargo

2026-07-30T10:30:28.000Z - 10 days ago

MannKind price target raised to $14 from $11 at Wells Fargo


MannKind Transcript: Study result

Jul 29, 2026, 4:30 PM EDT - 11 days ago

MannKind Transcript: Study result


MannKind Press release: Study result

Jul 29, 2026, 4:30 PM EDT - 11 days ago

MannKind Press release: Study result


MannKind Slides: Study result

Jul 29, 2026, 4:30 PM EDT - 11 days ago

MannKind Slides: Study result


MannKind reports ‘positive’ Phase 1b INFLO-1 results

2026-07-29T10:45:42.000Z - 11 days ago

MannKind reports ‘positive’ Phase 1b INFLO-1 results


MannKind Transcript: FDA announcement

Jul 24, 2026, 9:00 AM EDT - 16 days ago

MannKind Transcript: FDA announcement


MannKind Press release: FDA announcement

Jul 24, 2026, 9:00 AM EDT - 16 days ago

MannKind Press release: FDA announcement


MannKind Slides: FDA announcement

Jul 24, 2026, 9:00 AM EDT - 16 days ago

MannKind Slides: FDA announcement


MannKind announces FDA approval of Furoscix ReadyFlow

2026-07-24T10:41:33.000Z - 16 days ago

MannKind announces FDA approval of Furoscix ReadyFlow


MannKind announces $50M private placement

2026-07-24T10:40:57.000Z - 16 days ago

MannKind announces $50M private placement


MannKind Announces $50 Million Private Placement

Jul 24, 2026, 6:35 AM EDT - 16 days ago

MannKind Announces $50 Million Private Placement


MannKind price target raised to $11 from $10 at Wells Fargo

2026-06-01T01:10:05.000Z - 2 months ago

MannKind price target raised to $11 from $10 at Wells Fargo


MannKind Transcript: FDA announcement

May 29, 2026, 4:30 PM EDT - 2 months ago

MannKind Transcript: FDA announcement


US FDA approves MannKind's inhaled insulin for children

May 29, 2026, 12:44 PM EDT - 2 months ago

US FDA approves MannKind's inhaled insulin for children


MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026, 4:00 PM EDT - 2 months ago

MannKind to Present at Jefferies Global Healthcare Conference


MannKind Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

MannKind Transcript: AGM 2026


MannKind price target lowered to $7 from $8 at Mizuho

2026-05-07T15:49:43.000Z - 3 months ago

MannKind price target lowered to $7 from $8 at Mizuho


MannKind price target raised to $10 from $8 at H.C. Wainwright

2026-05-07T11:37:11.000Z - 3 months ago

MannKind price target raised to $10 from $8 at H.C. Wainwright


MannKind price target raised to $10 from $8 at Wells Fargo

2026-05-07T10:51:50.000Z - 3 months ago

MannKind price target raised to $10 from $8 at Wells Fargo


MannKind reports Q1 EPS (2c), consensus 1c

2026-05-07T01:17:30.000Z - 3 months ago

MannKind reports Q1 EPS (2c), consensus 1c


MannKind Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

MannKind Earnings Call Transcript: Q1 2026


MannKind Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

MannKind Earnings release: Q1 2026


MannKind Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

MannKind Quarterly report: Q1 2026


MannKind Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

MannKind Slides: Q1 2026


MannKind price target lowered to $8 from $10 at Mizuho

2026-04-13T14:45:40.000Z - 4 months ago

MannKind price target lowered to $8 from $10 at Mizuho


MannKind price target lowered to $6 from $7 at Truist

2026-04-08T12:35:39.000Z - 4 months ago

MannKind price target lowered to $6 from $7 at Truist


MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 4 months ago

MannKind Proxy statement: Proxy filing


MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 4 months ago

MannKind Proxy statement: Proxy filing


MannKind Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:40 PM EDT - 5 months ago

MannKind Transcript: Leerink Global Healthcare Conference 2026


MannKind Announces Settlement of Convertible Senior Notes

Mar 5, 2026, 4:30 PM EST - 5 months ago

MannKind Announces Settlement of Convertible Senior Notes


MannKind price target lowered to $8 from $10 at Wedbush

2026-03-05T14:03:29.000Z - 5 months ago

MannKind price target lowered to $8 from $10 at Wedbush

UTHR


MannKind to Participate in Upcoming Investor Conferences

Mar 4, 2026, 9:00 AM EST - 5 months ago

MannKind to Participate in Upcoming Investor Conferences


MannKind price target lowered to $7 from $8 at Wells Fargo

2026-02-27T12:57:54.000Z - 5 months ago

MannKind price target lowered to $7 from $8 at Wells Fargo


MannKind Earnings Call Transcript: Q4 2025

Feb 26, 2026, 9:00 AM EST - 5 months ago

MannKind Earnings Call Transcript: Q4 2025


MannKind Annual report: Q4 2025

Feb 26, 2026, 9:00 AM EST - 5 months ago

MannKind Annual report: Q4 2025


MannKind Earnings release: Q4 2025

Feb 26, 2026, 9:00 AM EST - 5 months ago

MannKind Earnings release: Q4 2025


MannKind Slides: Q4 2025

Feb 26, 2026, 9:00 AM EST - 5 months ago

MannKind Slides: Q4 2025


MannKind Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 7 months ago

MannKind Slides: Corporate presentation


MannKind Provides Business Updates and 2026 Growth Drivers

Jan 8, 2026, 8:05 AM EST - 7 months ago

MannKind Provides Business Updates and 2026 Growth Drivers


MannKind Shares FUROSCIX® Business Updates

Dec 23, 2025, 8:05 AM EST - 8 months ago

MannKind Shares FUROSCIX® Business Updates


MannKind Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 9 months ago

MannKind Transcript: Jefferies London Healthcare Conference 2025


MannKind Transcript: Study Update

Nov 10, 2025, 9:00 AM EST - 9 months ago

MannKind Transcript: Study Update


MannKind Press release: Study Update

Nov 10, 2025, 9:00 AM EST - 9 months ago

MannKind Press release: Study Update


MannKind Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

MannKind Earnings Call Transcript: Q3 2025


MannKind Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

MannKind Quarterly report: Q3 2025


MannKind Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

MannKind Earnings release: Q3 2025


MannKind Slides: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

MannKind Slides: Q3 2025


MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 4:05 PM EDT - 1 year ago

MannKind to Present at Upcoming Investor Conferences


MannKind Transcript: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 1 year ago

MannKind Transcript: M&A Announcement


MannKind Press release: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 1 year ago

MannKind Press release: M&A Announcement


MannKind Earnings Call Transcript: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q2 2025


MannKind Quarterly report: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Quarterly report: Q2 2025


MannKind Earnings release: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings release: Q2 2025


MannKind Slides: Corporate Presentation

Aug 6, 2025, 7:00 AM EDT - 1 year ago

MannKind Slides: Corporate Presentation


MannKind Slides: FY 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

MannKind Slides: FY 2025


MannKind Earnings Call Transcript: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q1 2025


MannKind Quarterly report: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Quarterly report: Q1 2025


MannKind Earnings release: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings release: Q1 2025


MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing


MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing


MannKind Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q4 2024


MannKind Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Annual report: Q4 2024


MannKind Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings release: Q4 2024


MannKind Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Slides: Q4 2024


amsteliam
amsteliam Aug. 9 at 11:25 PM
$MNKD This could go more quickly than I anticipated. Funny to say after 12 years.
0 · Reply
BenYiju
BenYiju Aug. 9 at 10:37 PM
$MNKD Mikey fired up the ATM again?!? 🤬
0 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 8:39 PM
0 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 7:57 PM
$MNKD this is a response to. How is 20 cartridges of Afrezza a day on the lungs?
0 · Reply
SS115
SS115 Aug. 9 at 7:44 PM
$MNKD Anyone know what the latest increase of 2.1 million OS count stems from? It went to 319.4 million after the initial shares from the private placement funding agreement were added but now it’s at 321.5 million. Was it from the private placement warrants being exercised, awarded shares to executives, or something else?
2 · Reply
JustAnotherJuggler
JustAnotherJuggler Aug. 9 at 7:27 PM
$MNKD these two reported in the last 12 hours
1 · Reply
grampslol
grampslol Aug. 9 at 7:00 PM
$MNKD and yet pennyland it is and shall be
1 · Reply
clan
clan Aug. 9 at 6:46 PM
$MNKD The first $200,000,000 of PROFIT that Mannkind makes from its scPharma division ... will be tax-free! 🤑 @DRFSR So they got that goin' for it, which is nice. 💲 $SCPH 👍 $SPY 💲
0 · Reply
grampslol
grampslol Aug. 9 at 4:36 PM
1 · Reply
clan
clan Aug. 9 at 4:33 PM
$MNKD Afrezza, INHALABLE mealtime insulin for diabetics, is now FDA approved for kids. It's also Scott Malkinson-approved. 🚫💉 For the good of all Mannkind. 👍 $LLY 😁 $NVO 👍 $SPY 🫵
0 · Reply
rooksleanne
rooksleanne Aug. 9 at 2:42 PM
2 · Reply
grampslol
grampslol Aug. 9 at 2:29 PM
$MNKD afrezza dpi inhaled prandial insulin approved in 2014 ... the only insulin with the FDA black box warning label... a pharmaceutical flop of epic proportions... #afizzle #pumpanddump
0 · Reply
Wolf1971
Wolf1971 Aug. 9 at 2:28 PM
$MNKD cmon MNKD shareholders don’t forget to write in your votes and send to Forbes magazine for Martine for lady ceo of the year kudos for breaking the glass ceiling
2 · Reply
rooksleanne
rooksleanne Aug. 9 at 2:04 PM
$MNKD https://www.linkedin.com/posts/spotted-in-new-york-city-big-milestones-ugcPost-7491579936961495041-SqI1/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAACOw9RUB8oDYv8dSI6pgi825MCKPJHLZK04&utm_campaign=share_via
0 · Reply
grampslol
grampslol Aug. 9 at 1:29 PM
0 · Reply
Arielsquare04
Arielsquare04 Aug. 9 at 1:25 PM
$MNKD furo is going to be a huge hit. If you could get afrezza covered for the kids this will be 40 a share in no time.
1 · Reply
grampslol
grampslol Aug. 9 at 1:12 PM
$MNKD The Company recorded no revenue and $0.1 million in revenue from commercial product sales to Cipla in India for the three and six months ended June 30, 2026. There were no commercial product sales to Cipla in India for the three and six months ended June 30, 2025.
0 · Reply
neil36
neil36 Aug. 9 at 1:12 PM
$MNKD Furoscix is drug number 4 in this video, mentioned about 85 seconds in https://youtu.be/2iIvERbgmzs?is=pTGMOPcOqePjjFU7
0 · Reply
Yourafool
Yourafool Aug. 9 at 1:08 PM
$MNKD grampstool having a break down. Weirdo gonna be posting non stop for ever and ever, what a life, at least he has himself to post to, no one else gives a shitt,
0 · Reply
grampslol
grampslol Aug. 9 at 1:03 PM
0 · Reply
clan
clan Aug. 9 at 12:46 PM
$MNKD Here's why hype and exuberance around Mannkind's progress will likely propel MNKD to over $50/sh by the end of 2028... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $1 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approved Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $8 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug -------- +$48/sh Take a 👀 🫵 $SPY and $QQQ 🤑
0 · Reply
Rungreen
Rungreen Aug. 9 at 12:43 PM
$MNKD I know this isn’t popular, but they need a R/S to lower the overall outstanding share count. 1 for 10.
4 · Reply